Abstract
In this chapter, an overview of in vivo induced antigen technology (IVIAT) and change mediated antigen technology (CMAT) will be presented, including a discussion of the advantages and limitations of these methods. Over fifteen different microbial pathogens have been or are known to be currently studied with these methods. Salient data obtained from the application of IVIAT and/or CMAT to a selection of human and plant pathogens will be summarized. This includes recent reports on Streptococcus pyogenes (Group A) in neurological disorders and invasive diseases, Xylella fastidiosa in Pierces disease, Xanthomonas campestris in bean blight, Salmonella enterica serovar typhi in typhoid fever and Leishmania spp. related infections. Special emphasis will be given to those targets that have been further investigated for the development of novel vaccine, diagnostic and/or antibiotherapy strategies. This encompasses a new point-of-care serological diagnostic test for chronic periodontal diseases. Finally, Mycobacterium tuberculosis in vivo induced products will be described as providing a rational basis for differentiating subjects with primary, dormant or secondary tuberculosis infections, from control subjects who have or did not have prior vaccination with BCG.
Keywords: Virulence, pathogenesis, bacterium, parasite, IVIAT, CMAT, IVET, STM, DFI
Infectious Disorders - Drug Targets
Title: In Vivo Induced Antigen Technology (IVIAT) and Change Mediated Antigen Technology (CMAT)
Volume: 6 Issue: 3
Author(s): Martin Handfield and Jeffrey D. Hillman
Affiliation:
Keywords: Virulence, pathogenesis, bacterium, parasite, IVIAT, CMAT, IVET, STM, DFI
Abstract: In this chapter, an overview of in vivo induced antigen technology (IVIAT) and change mediated antigen technology (CMAT) will be presented, including a discussion of the advantages and limitations of these methods. Over fifteen different microbial pathogens have been or are known to be currently studied with these methods. Salient data obtained from the application of IVIAT and/or CMAT to a selection of human and plant pathogens will be summarized. This includes recent reports on Streptococcus pyogenes (Group A) in neurological disorders and invasive diseases, Xylella fastidiosa in Pierces disease, Xanthomonas campestris in bean blight, Salmonella enterica serovar typhi in typhoid fever and Leishmania spp. related infections. Special emphasis will be given to those targets that have been further investigated for the development of novel vaccine, diagnostic and/or antibiotherapy strategies. This encompasses a new point-of-care serological diagnostic test for chronic periodontal diseases. Finally, Mycobacterium tuberculosis in vivo induced products will be described as providing a rational basis for differentiating subjects with primary, dormant or secondary tuberculosis infections, from control subjects who have or did not have prior vaccination with BCG.
Export Options
About this article
Cite this article as:
Handfield Martin and Hillman D. Jeffrey, In Vivo Induced Antigen Technology (IVIAT) and Change Mediated Antigen Technology (CMAT), Infectious Disorders - Drug Targets 2006; 6 (3) . https://dx.doi.org/10.2174/187152606778249908
DOI https://dx.doi.org/10.2174/187152606778249908 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nano Particles: Emerging Warheads Against Bacterial Superbugs
Current Topics in Medicinal Chemistry Transition-State-Guided Drug Design for Treatment of Parasitic Neglected Tropical Diseases
Current Medicinal Chemistry The Potential of Ganoderma Lucidum as Antimicrobial Agent for Multidrug- Resistant Mycobacterium Tuberculosis
Anti-Infective Agents Synthesis and SAR Evaluation of Mercapto Triazolobenzothiazole Derivatives as Anti-tuberculosis Agents
Anti-Infective Agents Development and Validation of a Liquid Chromatographic Method for Aroylhydrazones at Hydrolytic Conditions
Current Pharmaceutical Analysis Gene Mining and Functional Genomics in Human Osteoarthritis
Current Genomics Is the Deficiency of Vitamin B12 Related to Oxidative Stress and Neurotoxicity in Parkinsons Patients?
CNS & Neurological Disorders - Drug Targets Patent Selections
Recent Patents on DNA & Gene Sequences Recent Advances in Medicinal Chemistry to Treat Tuberculosis – Part-II
Current Topics in Medicinal Chemistry Multiple Myeloma or Brucellosis: A Case Report
Infectious Disorders - Drug Targets Biosynthesis of Plant Triterpenoid Saponins: Genes, Enzymes and their Regulation
Mini-Reviews in Organic Chemistry Anti-Tuberculosis Drug Induced Hepatotoxicity and Genetic Polymorphisms in Drug-metabolizing Genes
Current Pharmacogenomics Short Antimicrobial Peptides
Recent Patents on Anti-Infective Drug Discovery Aminobisphosphonates as New Weapons for γ δ T Cell-Based Immunotherapy of Cancer
Current Medicinal Chemistry Podophyllotoxin: Current Perspectives
Current Bioactive Compounds Recursive Partitioning Analysis and Anti-Tubercular Screening of 3- Aminopyrazine-2-Carbohydrazide Derivatives
Letters in Drug Design & Discovery Anti-Arthritic Effects of Immunomodulatory Peptide Injected in Joints
Current Drug Delivery Carnitine Metabolism and Deficit - When Supplementation is Necessary?
Current Pharmaceutical Biotechnology Structural Requirements for Efficient Phosphorylation of Nucleotide Analogs by Human Thymidylate Kinase
Mini-Reviews in Medicinal Chemistry An Update on Natural Products with Carbonic Anhydrase Inhibitory Activity
Current Pharmaceutical Design